

LZI Oral Fluid Opiate Enzyme Immunoassay

REF S0020c (75/37.5 mL R₁/R₂ Kit)
S0021c (750/375 mL R₁/R₂ Kit)



For Forensic Use Only

Lin-Zhi International, Inc.

Intended Use

The Lin-Zhi International, Inc. (LZI) Oral Fluid Opiate Enzyme Immunoassay is a homogeneous enzyme immunoassay intended for the qualitative and semi-quantitative determination of opiates in neat human oral fluid, collected into an LZI Oral Fluid Collector, at the cutoff value of 40 ng/mL. The assay is designed for use with a number of automated clinical chemistry analyzers. This is a non-FDA approved assay for Forensic Use Only and as such should not be repackaged for *in vitro* diagnostic use.

The assay provides only a preliminary analytical result. A more specific alternative analytical chemistry method must be used in order to obtain a confirmed analytical result. Gas or Liquid Chromatography/Mass Spectrometry (GC/MS or LC/MS) is the preferred confirmatory method (1, 2). Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

Summary and Explanation of Test

Opiates are naturally occurring alkaloids derived from the opium poppy, *Papaver somniferum* (3). Common opiates include morphine, codeine, and heroin, which is a semi-synthetic derivative of morphine. Oral fluid testing for opiates is now well accepted (4, 5).

Morphine and codeine are potent analgesics. They are among the most effective and common medications for treatment of mild to severe pain. These legitimate drugs, however, are frequently abused for their central nervous system (CNS) effects. Heroin is the most commonly abused opiate (6). It may be snorted, smoked, or dissolved and injected subcutaneously or intravenously.

Opiates are absorbed rapidly and primarily metabolized in the liver (6-8). Heroin is converted quickly to 6-acetylmorphine or morphine, which is excreted in urine both unchanged and as glucuronide conjugates. Excretion in urine takes place over two to three days. Detection times for drugs in oral fluid are roughly similar to that in blood; approximately 1-24 hours (9). Oral fluid normally contains parent drug rather than drug metabolites, which are more commonly detected in urine. The presence of opiates in oral fluid indicates the use of heroin, morphine, codeine, and/or other synthetic opiates structurally related to morphine, such as hydromorphone and oxycodone.

Assay Principle

The LZI Oral Fluid Opiate Enzyme Immunoassay is a homogeneous enzyme immunoassay with ready-to-use liquid reagents. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent (10). Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, morphine-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. On the other hand, when drug is present in the sample, antibody binds to free drug and the unbound morphine-labeled G6PDH then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at 340 nm.

Reagents Provided

Antibody/Substrate Reagent (R₁): Contains mouse monoclonal anti-morphine antibody, glucose-6-phosphate (G6P), nicotinamide adenine dinucleotide (NAD), stabilizers, and sodium azide (0.09 %) as a preservative.

Enzyme-drug Conjugate Reagent (R₂): Contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with morphine in buffer with sodium azide (0.09 %) as a preservative.

Calibrators and Controls*

*Calibrators and Controls are sold separately and contain negative synthetic oral fluid matrix with Proclin 300™ as a preservative.

ORAL FLUID OPIATE Calibrators	REF #
Oral Fluid LIS Negative Calibrator	S0008
Low Calibrator: Contains 20 ng/mL morphine	S0022c
Cutoff Calibrator: Contains 40 ng/mL morphine	S0023c
Intermediate Calibrator: Contains 60 ng/mL morphine	S0024c
High Calibrator: Contains 80 ng/mL morphine	S0025c
ORAL FLUID OPIATE Controls	REF #
Level 1 Control: Contains 30 ng/mL morphine	S0027c
Level 2 Control: Contains 50 ng/mL morphine	S0028c

Collector **

**Collector is sold separately.

ORAL FLUID Collector	REF #
LZI Oral Fluid Collector -50 mL Polypropylene Centrifuge Tube	S0000b

Precautions and Warning

- This test is a non-FDA approved assay and is for Forensic Use Only. This test should not be repackaged for *in vitro* diagnostic use.
- Harmful if swallowed.
- Reagent contains sodium azide as a preservative, which may form explosive compounds in metal drain lines. When disposing such reagents or wastes always flush with a large volume of water to prevent azide build-up. See National Institute for Occupational Safety and Health Bulletin: Explosive Azide Hazards (11).
- Do not use the reagents beyond their expiration dates.

Reagent Preparation and Storage

The reagents are ready-to-use. No reagent preparation is required. All assay components should be refrigerated at 2-8°C when not in use.

Specimen Storage and Shipping

Note: If oral fluid samples cannot be analyzed immediately, they may be stored in amber glass vials and refrigerated (2-8°C) for up to 21 days or frozen (-20°C) for up to 21 days (13). Studies have been performed up to 21 days to show morphine is stable in oral fluid. No further study was conducted beyond 21 days.

Samples should always be shipped cold (2-8°C), packed in gel ice, and shipped for next day delivery (within 24 hours). Failure to store or ship samples under these conditions may result in a significant decrease in recovery of analyte. Please see additional details in the Specimen Collection and Handling section below.

Specimen Collection and Handling

Oral fluid samples should be collected into a device without an absorbing pad, such as the LZI Oral Fluid Collector (a 50 mL polypropylene centrifuge tube) (12).

Prior to testing, samples should be frozen overnight (at minimum) and then allowed to thaw at room temperature. Samples should then be spun for five minutes at 3000 rpm to remove particulates. Only the clear top layer should be assayed for EIA testing and/or confirmatory testing. Samples should be at room temperature (18-25°C) for testing.

Samples do not require dilution or any additional correction factors. Handle all oral fluid specimens as if they are potentially infectious.

Instrument

Clinical chemistry analyzers capable of maintaining a constant temperature, pipetting sample, mixing reagents, measuring enzyme rates at 340 nm, and timing the reaction accurately can be used to perform this homogeneous enzyme immunoassay. Performance characteristics presented in this package insert have been validated on the Hitachi 717. If other instruments are used, performance will need to be validated by the laboratory.

Assay Procedure

Analyzers with specifications indicated above are suitable for performing this homogeneous enzyme immunoassay. Refer to the specific parameters used for each analyzer before performing the assay. Typical assay parameters used for the Hitachi 717 analyzer include a 60 µL sample, 135 µL of antibody reagent (R₁), and 68 µL of enzyme conjugate reagent (R₂) in 37°C incubation temperature, 30-35 reading frames, and 340 nm primary wavelength.

For qualitative analysis, use the 40 ng/mL cutoff calibrator. For semi-quantitative analysis, use all five calibrators and two controls. Recalibration should be performed after reagent bottle change or a change in calibrators or reagent lot. Two levels of controls are available for monitoring the cutoff level: 30 ng/mL and 50 ng/mL.

Calibration and Quality Control

Good laboratory practices recommend the use of at least two levels of control specimens (one positive and one negative control near the cutoff) to ensure proper assay performance. Controls should be run with each new calibration and after specific maintenance or troubleshooting procedures as detailed in the instrument system manual. Each laboratory should establish its own quality control frequency. If any trends or sudden change in control value are observed, review all operating parameters, or contact LZI technical support for further assistance. Laboratories should comply with all federal, state, and local laws, guidelines, and regulations.

Results

Note: A preliminary positive test result does not always mean a person took illegal drugs and a negative test result does not always mean a person did not take illegal drugs. There are number of factors that influence the reliability of drug tests.

Qualitative: The cutoff calibrator, which contains 40 ng/mL of morphine, is used as a reference for distinguishing a preliminary positive from negative samples. A sample with a change in absorbance ($\Delta mA/min$) equal to or greater than that obtained with the cutoff calibrator is considered a preliminary positive. A sample with a change in absorbance ($\Delta mA/min$) lower than that obtained with the cutoff calibrator is considered negative.

Semi-Quantitative: The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for verification by a confirmatory method such as GC/MS or LC/MS, or (2) permitting laboratories to establish quality control procedures. This mode requires a calibration curve that can be established with the five assay calibrators and two controls.

Limitations

1. A preliminary positive result from the assay indicates only the presence of morphine. The test is not intended for quantifying this single analyte in samples.
2. A preliminary positive result does not necessarily indicate drug abuse.
3. A negative result does not necessarily mean a person did not take morphine.
4. There is a possibility that other substances and/or factors not listed above may interfere with the test and cause incorrect results (e.g., technical or procedural error, fluid intake, endogenous or exogenous interferents).
5. Preliminary positive results should be confirmed by other affirmative, analytical chemistry methods (e.g., chromatography), preferably GC/MS or LC/MS.
6. The test is designed for use with human oral fluid only.

Bibliography:

1. Urine Testing for Drug of Abuse, National Institute on Drug Abuse (NIDA) Research Monograph **73** (1986).
2. Mandatory Guidelines for Federal Workplace Drug Testing Program, National Institute on Drug Abuse, Federal Register, **69**(71): 19644 (2004).
3. Balant L.P. and Balant-Gorgia, A.E., Opium and its derivatives. *Clin Ther.* **14**: 846 (1992).
4. Cone, E.J., Legal, workplace, and treatment drug testing with alternative biological matrices on a global scale. *Forensic Sci. Int.* **121**:7, (2001).
5. Caplan, Y.H. and Goldberger, B.A., Alternative specimens for workplace drug testing. *J. Anal. Toxicol.* **25**:396 (2001).
6. Glare, P.A., and Walsh, T.D., Clinical Pharmacokinetics of morphine. *Ther. Drug Monit.* **13**: 1 (1991).
7. Cone, E.J., Welch, P., Mitchell, J.M., and Paul, B.D., Forensic drug testing for opiates, I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. *J. Anal. Toxicol.* **15**: 17 (1991).
8. Hasselstrom, J. and Sawe, J., Morphine pharmacokinetics and metabolism in humans: Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. *Clin Pharmacokinet.* **24**: 344 (1993).
9. Huestis, M.A., and Cone, E.J., Alternative testing matrices. In *Drug Abuse Handbook*, S. Karch, Ed. CRC Press, Boca Raton, FL, 799-857 (1988).
10. Rubenstein, K.E., Schneider, R.S., and Ullman, E.F., Homogeneous Enzyme Immunoassay: A New Immunochemical Technique, *Biochem Biophys Res Commun.* **47**, 846 (1972).
11. Sodium Azide. National Institute for Occupational Safety (NIOSH). Pocket Guide to Chemical Hazards. Third Printing, September 2007. Available online at: <https://www.cdc.gov/niosh/npg/default.html>
12. LZI Oral Fluid Sample Preparation Sheet.
13. Ventura, M., Pichini, S., Ventura, R., Zuccaro, P., Pacifici, R., and de la Torre, R., Stability Studies of Principal Illicit Drugs in Oral Fluid: Preparation of Reference Materials for External Quality Assessment Schemes. *Ther. Drug. Monit.* **29**(5):662-665 (2007).

Additions, deletions, or changes are indicated by a change bar in the margin.

For technical assistance please call: (408) 970-8811

Manufacturer:

Lin-Zhi International, Inc.

2945 Oakmead Village Court

Santa Clara, CA 95051

USA

Tel: (408) 970-8811

Fax: (408) 970-9030

www.lin-zhi.com

© February 2020 Rev. 7